These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38169137)

  • 1. Safety and tolerability of intravenous immunoglobulin infusion in Down syndrome regression disorder.
    Santoro JD; Jafarpour S; Khoshnood MM; Boyd NK; Vogel BN; Nguyen L; Saucier LE; Partridge R; Tiongson E; Ramos-Platt L; Nagesh D; Ho E; Rosser T; Ahsan N; Mitchell WG; Rafii MS
    Am J Med Genet A; 2024 May; 194(5):e63524. PubMed ID: 38169137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse childhood experiences and the development of Down syndrome regression disorder.
    Wang S; Patel L; Sannar EA; Khoshnood M; Boyd NK; Mendez L; Spinazzi NA; Quinn EA; Rafii MS; Santoro JD
    Am J Med Genet A; 2023 Jul; 191(7):1769-1782. PubMed ID: 37017126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative Diagnoses in the Work Up of Down Syndrome Regression Disorder.
    Santoro JD; Khoshnood MM; Nguyen L; Vogel BN; Boyd NK; Paulsen KC; Rafii MS
    J Autism Dev Disord; 2023 Aug; ():. PubMed ID: 37584771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroimaging abnormalities associated with immunotherapy responsiveness in Down syndrome regression disorder.
    Santoro JD; Khoshnood MM; Jafarpour S; Nguyen L; Boyd NK; Vogel BN; Kammeyer R; Patel L; Manning MA; Rachubinski AL; Filipink RA; Baumer NT; Santoro SL; Franklin C; Tamrazi B; Yeom KW; Worley G; Espinosa JM; Rafii MS
    Ann Clin Transl Neurol; 2024 Apr; 11(4):1034-1045. PubMed ID: 38375538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: a retrospective analysis of 1085 infusions.
    Rigas M; Tandan R; Sterling RJ
    J Clin Neuromuscul Dis; 2008 Dec; 10(2):52-5. PubMed ID: 19169090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders.
    Souayah N; Hasan A; Khan HM; Yacoub HA; Jafri M
    J Clin Neuromuscul Dis; 2011 Jun; 12 Suppl 4():S1-10. PubMed ID: 22361589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy responsiveness and risk of relapse in Down syndrome regression disorder.
    Santoro JD; Spinazzi NA; Filipink RA; Hayati-Rezvan P; Kammeyer R; Patel L; Sannar EA; Dwyer L; Banerjee AK; Khoshnood M; Jafarpour S; Boyd NK; Partridge R; Gombolay GY; Christy AL; Real de Asua D; Del Carmen Ortega M; Manning MA; Van Mater H; Worley G; Franklin C; Stanley MA; Brown R; Capone GT; Quinn EA; Rafii MS
    Transl Psychiatry; 2023 Aug; 13(1):276. PubMed ID: 37553347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance study on the tolerability and safety of Flebogamma
    Alsina L; Mohr A; Montañés M; Oliver X; Martín E; Pons J; Drewe E; Papke J; Günther G; Chee R; Gompels M;
    Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulin for the treatment of Kawasaki disease.
    Broderick C; Kobayashi S; Suto M; Ito S; Kobayashi T
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014884. PubMed ID: 36695415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De novo variants in immune regulatory genes in Down syndrome regression disorder.
    Jafarpour S; Banerjee AK; Khoshnood MM; Vogel BN; Boyd NK; Nguyen L; Partridge R; Santoro SL; Gombolay GY; Fisher KS; de Asua DR; Del Ortega MC; Franklin C; Rafii MS; Santoro JD
    J Neurol; 2024 Aug; 271(8):5567-5576. PubMed ID: 38909119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.
    Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D
    Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immediate adverse events to intravenous immunoglobulin in pediatric patients with inborn errors of immunity: A longitudinal study with a pre-infusion protocol.
    Antunes TS; Melo KM; Valente CFC; Tavares FS
    Hematol Transfus Cell Ther; 2023; 45(2):253-258. PubMed ID: 36114118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study.
    Aggarwal R; Schessl J; Charles-Schoeman C; Bata-Csörgő Z; Dimachkie MM; Griger Z; Moiseev S; Oddis CV; Schiopu E; Vencovský J; Beckmann I; Clodi E; Levine T;
    Arthritis Res Ther; 2024 Jan; 26(1):27. PubMed ID: 38233885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy Responsiveness and Risk of Relapse in Down Syndrome Regression Disorder.
    Santoro J; Spinazzi N; Filipink R; Hayati-Rezvan P; Kammeyer R; Patel L; Sannar E; Dwyer L; Banerjee A; Khoshnood M; Jafarpour S; Boyd N; Partridge R; Gombolay G; Christy A; Real de Asua D; Del Carmen Ortega M; Manning M; Van Mater H; Worley G; Franklin C; Stanley M; Brown R; Capone G; Quinn E; Rafii M
    Res Sq; 2023 Feb; ():. PubMed ID: 36824719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion.
    Kato H; Hayashi M; Ohashi W; Yamaguchi T; Tanaka S; Kozono A; Gao S; Katai A; Niwa R; Matsuo T; Ishiyama K; Ando T; Ogawa M; Nakayama T
    Front Immunol; 2021; 12():740517. PubMed ID: 34603326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptoms of Catatonia Observed in Down Syndrome Regressive Disorder: A Retrospective Analysis.
    Smith JR; Baldwin I; Lim S; Luccarelli J
    J Autism Dev Disord; 2024 Feb; ():. PubMed ID: 38386254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.
    Nobile-Orazio E; Cocito D; Jann S; Uncini A; Beghi E; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Macchia R; Cavaletti G; Giannini F; Sabatelli M;
    Lancet Neurol; 2012 Jun; 11(6):493-502. PubMed ID: 22578914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors of first dosage intravenous immunoglobulin-related adverse effects in children.
    Kubota J; Hamano SI; Daida A; Hiwatari E; Ikemoto S; Hirata Y; Matsuura R; Hirano D
    PLoS One; 2020; 15(1):e0227796. PubMed ID: 31929600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse reactions and influencing factors in children with primary immunodeficiencies receiving intravenous immunglobulin replacement.
    Ibis IBP; Erdur B; Erdem SB; Karaman S; Gulez N; Genel F
    Allergol Immunopathol (Madr); 2020; 48(6):738-744. PubMed ID: 32703652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.
    Bichuetti-Silva DC; Furlan FP; Nobre FA; Pereira CT; Gonçalves TR; Gouveia-Pereira M; Rota R; Tavares L; Mazzucchelli JT; Costa-Carvalho BT
    Int Immunopharmacol; 2014 Dec; 23(2):442-6. PubMed ID: 25257732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.